The FDA also gave full approval to the Novavax COVID vaccine (Nuvaxovid) using this approach, approving it for those ages 65 and up, along with people ages 12 and up who have at least one underlying condition that puts them at risk of severe disease.

No, this is not true. Vaccines undergo rigorous safety testing and are continuously monitored for adverse events.

The US Food and Drug Administration has fully approved a new COVID vaccine option specifically targeting high-risk individuals, including seniors. The protein-based Nuvaxovid vaccine, produced by Novavax,

The most commonly reported adverse events with the AZD1222 COVID-19 vaccine are headache and fatigue, a large-scale active surveillance study from the United Kingdom shows.

FDA FLAGS SEVERE ITCH — Patients who stop using the oral allergy medicines cetirizine (Zyrtec) or levocetirizine (Xyzal) may experience rare but severe itching after longtime use, the FDA has cautioned.

Under a new policy announced Tuesday by the Trump administration, only people age 65 and older and children or young adults with certain health conditions that puts them at risk will be approved for the shot.

U.S. regulators will no longer approve COVID booster shots for healthy adults and children without new studies, adding a costly requirement for drugmakers, though they will still be available for millions of high-risk Americans.

Late-stage trial data suggest that a new COVID-flu vaccine offers good protection against both infections, but experts expect the shot's approval may be delayed.